Abstract
The efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.
MeSH terms
-
Aged
-
Contraindications
-
Fibrinolytic Agents / administration & dosage
-
Fibrinolytic Agents / therapeutic use*
-
Humans
-
Myocardial Infarction / drug therapy*
-
Myocardial Infarction / pathology
-
Practice Guidelines as Topic
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / therapeutic use*
-
Tenecteplase
-
Thrombolytic Therapy / adverse effects
-
Thrombolytic Therapy / trends*
-
Tissue Plasminogen Activator / administration & dosage
-
Tissue Plasminogen Activator / therapeutic use*
Substances
-
Fibrinolytic Agents
-
Recombinant Proteins
-
reteplase
-
Tissue Plasminogen Activator
-
Tenecteplase